Bone cancer in 2011: Prevention and treatment of bone metastases

Nature Reviews Clinical Oncology

Volumn 9, Issue 2, 2012, Pages 76-78

  Coleman, Robert E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; DENOSUMAB; GOSERELIN; PLACEBO; RADIUM CHLORIDE RA 223; TAMOXIFEN; ZOLEDRONIC ACID;

ADVANCED CANCER; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; DRUG COST; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG USE; HUMAN; LUNG NON SMALL CELL CANCER; MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; TREATMENT DURATION;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; HISTORY, 21ST CENTURY; HUMANS;

EID: 84856611805     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.198     Document Type: Review

References (10)

1. Stopeck, A. T. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28, 5132-5139 (2010).
2. Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813-822 (2011).
3. Henry, D. H. et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29, 1125-1132 (2011).
4. Saad, F. et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann. Oncol. http://dx.doi.org/ 10.1093/annonc/mdr435.
5. Parker, C. et al. Overall survival benefit of radium-223 chloride (alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomised trial (ALSYMPCA) [abstract]. Eur. J. Cancer 47 (Suppl. 2), a3 (2011).
6. Gnant, M. et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679-691 (2009).
7. Gnant, M. et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 12, 631-641 (2011).
8. Gnant, M. et al. Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12 [abstract]. J. Clin. Oncol. 29 (Suppl. 15), a520 (2011).
9. Coleman, R. E. et al. Breast-cancer adjuvant therapy with and without zoledronic acid. N. Engl. J. Med. 365, 1396-1405 (2011).
10. Smith, M. R. et al. Denosumab and bone metastasis-free survival in men with castration-resistant prostate cancer: results of a global phase 3, randomised, placebo-controlled trial. Lancet http://dx.doi.org/10.1016/S0140- 6736(11)61226-9.